pubmed.ncbi.nlm.nih.gov

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study) - PubMed

️Mon Jan 01 2024

Observational Study

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)

Irene Caballero Mateos et al. Nutrients. 2024.

Abstract

Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting. An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain. We evaluated changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. Additionally, we analyzed different subgroups of patients treated with semaglutide OW s.c. as an add-on to glucose-lowering therapy. A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included. At 12 months, compared with baseline, there was a mean difference of -2.1% in HbA1c levels (p < 0.001) and a mean difference of 9.2 kg in body weight (p < 0.001). Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy. Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects. In this RW study, 12 months of treatment with semaglutide OW s.c. in patients with T2DM was associated with significant and clinically relevant improvements in glycemic control and weight loss, regardless of the glucose-lowering therapy received, and the overall safety profile was positive.

Keywords: body weight; glucagon-like peptide-1 receptor agonist; glycemic control; once weekly semaglutide; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

J.C.F.-G. has received speaker honoraria from Novo Nordisk, Lilly, Boehringer-Ingelheim, Esteve, Menarini, and AstraZeneca. The rest of the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**Figure 1**
Flow diagram of patients’ disposition.

**Figure 2**
Change in (A) glycated hemoglobin (HbA1c), and (B) body weight (kg), over the study time. MD = mean difference; CI = confidence interval.

References

1. ElSayed N.A., Aleppo G., Aroda V.R., Bannuru R.R., Brown F.M., Bruemmer D., Collins B.S., Gaglia J.L., Hilliard M.E., Isaacs D., et al. 2. Classification and diagnosis of diabetes: Standards of care in diabetes-2023. Diabetes Care. 2023;46:S19–S40. doi: 10.2337/dc23-S002. - DOI - PMC - PubMed
1. Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of type 2 diabetes—Global burden of disease and forecasted trends. J. Epidemiol. Glob. Health. 2020;10:107–111. doi: 10.2991/jegh.k.191028.001. - DOI - PMC - PubMed
1. European Commission Diabetes. [(accessed on 3 July 2024)]. Available online: https://research-and-innovation.ec.europa.eu/research-area/health/diabet....
1. Davies M.J., Aroda V.R., Collins B.S., Gabbay R.A., Green J., Maruthur N.M., Rosas S.E., Del Prato S., Mathieu C., Mingrone G., et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) Diabetes Care. 2022;45:2753–2786. doi: 10.2337/dci22-0034. - DOI - PMC - PubMed
1. Gomez-Peralta F., Martín F.J.E.S., Torre E.M., Cases M.M., García J.C.F., Loiola P.E., Lachica L., Pérez J.A.F., Menéndez S.A., Álvarez-Guisasola F., et al. Spanish diabetes society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 update. Endocrinol. Diabetes Nutr. (Engl. Ed.) 2018;65:611–624. doi: 10.1016/j.endien.2018.11.010. - DOI - PubMed

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study) - PubMed